Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

177.49USD
12:08pm EDT
Change (% chg)

$-0.67 (-0.38%)
Prev Close
$178.16
Open
$177.65
Day's High
$178.08
Day's Low
$176.84
Volume
226,140
Avg. Vol
338,266
52-wk High
$209.20
52-wk Low
$161.09

Select another date:

Mon, Mar 27 2017

Patent trial begins in Shire bid to block generic Adderall XR

Shire PLC's bid to prevent a Florida-based drug company from being able to go to market with a generic version of extended-release Adderall entered the courtroom phase on Monday as a bench trial began.

BRIEF-FDA grants fast track designation for Shire's Recombinant ADAMTS13

* Shire receives FDA fast track designation for Recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura Source text for Eikon: Further company coverage:

BRIEF-FDA grants fast track designation for Shire's Recombinant Adamts13

* Shire Plc - United States Food And Drug Administration (FDA) has granted fast track designation for Recombinant Adamts13

BRIEF-Shire receives European approval for label extension of Cinryze

* Shire receives european approval for label extension of Cinryze(C1 inhibitor) to prevent and treat hereditary angioedema (HAE) attacks in paediatric patients with hae

BRIEF-Neos Therapeutics enters into a license agreement with Shire

* On March 6, 2017, Neos Therapeutics entered into a license agreement with Shire - SEC filing

BRIEF-Argenx announces extension of therapeutic antibody alliance with Shire

* Reg-Argenx announces extension of therapeutic antibody alliance with Shire plc to advance the discovery and development of novel human therapeutic antibodies for diverse rare and unmet diseases for a further year until May 30, 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab

* No serious adverse events or discontinuations due to adverse events were observed at all doses studied

UPDATE 2-China updates key drug list in boost for Big Pharma

* GSK, AZ, Shire welcome update (Adds GSK statement, analyst comment, details)

Pharma group Shire produces top-of-the-range earnings

LONDON Pharmaceuticals group Shire on Thursday said it was extremely optimistic about long-term growth after reporting a 12 percent rise in earnings for the past year in which it made its largest ever acquisition.

UPDATE 1-Pharma group Shire produces top-of-the-range earnings

* Shares rise 6 pct (Adds CEO comments, analyst reaction, shares)

Select another date:

More From Around the Web